[1] LI J T，WEINSTEIN A J，YANG M.Surveillance of bacterial resistance in China (1998-1999) [J] .Natl Med J China（中华医学杂志），2001，81（1）：8-16. [2] WU A H，REN N，WEN X M，et al.Analysis of the data from national nosocomial infection surveillance system between 1998 and 1999[J] .Chin J Nosocomiol（中华医院感染学杂志），2000，10（6）：401-403. [3] KUTI J J，NICOLAU D P.Making the most of surveillance studies summary of the OPTAMA program[J] .Diagn Microbiol Infect Dis，2005，53（4）：281- 287. [4] CRAIG W A.Pharmacokinetic/pharmacodynamic parameters：rationale for antibacterial dosing of mice and men[J] .Clin Infect Dis，1998，26（1）：1- 10. [5] MATTOES H M，KUTI J L，DRUSANO G L，et al. Optimizing antimicrobial pharmacodynamics：dosage strategies for meropenem[J] .Clin Ther，2004，26（8）：1187- 1198. [6] LI J T，JI H M，LI Y，et al.2002-2003 Bacterial resistance surveillance on Gram-positive cocci isolated from hospital acquired infections and community acquired infections in China [J] .Chin J Lab Med（中华检验医学杂志），2005，28（3）：254-265. [7] TURNIDGE J D.The pharmacodynamics of beta-lactams[J] .Clin Infect Dis，1998，27（1）：10-22. [8] DRUSANO G L.Prevention of resistance：A goal for dose selection of antimicrobial agents[J] . Clin Infect Dis，2003，36(Suppl 1)：42-50. [9] MOORE R D，LIETMAN P S，SMITH C R.Clinical response to aminoglycoside therapy：Importance of the ratio of peak concentration to minimal inhibitory concentration[J] .J Infect Dis，1987，155（1）：93-99. [10] WRIGHT D H，BROWN G H，PETERSON M L，et al.Application of fluoroquinolone pharmacodynamics[J] .J Antimicrob Chemother，2000，46（5）：669-683. [11] PRESTON S L，DRUSANO G L，BERMAN A L，et al.Pharmaco-dynamics of levofloxacm：A new paradigm for early clinical trials[J] .JAMA，1998，279（2）：125-129. [12] LACY M K，LU W，XU X，et al.Pharmacodynamic comparisons of levofloxacin，ciprofloxacin，and ampicillm against Streptococcus pncumoniae in an in vitro model of infection[J] .Antimicrob Agents Chemother，1999，43（3）：672-677. [13] BRADLEY J S，DUDLEY M N，DRUSANO G L.Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation[J] .Pediatr Infect Dis J，2003，22（11）：982-992. [14] AMBROSE P G，GRASELA D M.The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs：fluoroquinolone pharmacodynamics against Streptococcus pneumoniae[J] . Diagn Microbiol Infect Dis，2000，38（3）：151-157. [15] AMBROSE P G，BHAVNANI S M，JONES R N. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extendedspectrum beta-lactamases：report from the ARREST Program[J] .Antimicrob Agents Chemother，2003，47（5）：1643- 1646. [16] DRUSANO G L，PRESTON S L，HARDALO C，et al.Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint antimicrobial pharmacodynamics：dosage strategies for meropenem[J] .Clin Ther，2001，26（8）：1187- 1198. [17] MOUTON J W，SCHMITT-HOFFMANN A，SHAPIRO S，et al.Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141[J] .Antimicrob Agents Chemother，2004，48（5）：1713-1718. [18] WANG H，ZHANG B，NI Y X，et al.Pharmacodynamic target attainment of seven antimicrobials against Gram-negativebacteria collected from China in 2003 and 2004[J] .Int J Antimicrob Agents，2007，30（5）：452-457. [19] MOUTON J W，DUDLEY M N，CARS O，et al.Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs：an update[J] .J Antimicrob Chemother，2005，55（5）：601-607. [20] KUTI J L，HOROWITZ S，NIGHTINGALE C H，et al.Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem[J] . Pharmacotherapy，2005，25（7）：935-941. [21] MOUTON J W，PUNT N，VINKS A A.A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers，patients with cystic fibrosis，and patients in the intensive care unit[J] .Clin Ther，2005，27（6）：762- 772. [22] KIFFER C R，MENDES C，KUTI J L，et al.Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli，Klebsiella pneumoniae，Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program：the OPTAMA Program，South America 2002[J] .Diagn Microbiol Infect Dis，2004，49（2）：109- 116. [23] KUTI J L，NIGHTINGALE C H，NICOLAU D P.Optimizing Pharmacodynamic Target Attainment using the MYSTIC Antibiogram：data collected in North America in 2002[J] .Antimicrob Agents Chemother，2004，48（7）：2464-2470. [24] KOTAPATI S，KUTI J L，NICOLAU D P.Pharmacodynamic modeling of Blactam antibiotics for the empiric treatment of secondary peritonitis：a report from the OPTAMA Program[J] .Surg Infect，2005，6（3）：297- 304. [25] MAGLIO D，KUTI J L，NICOLAU D P.Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections：a report from the OPTAMA program[J] . Clin Ther，2005，27（7）：1032-1042. [26] ONG C T，KUTI J L，NICOLAU D P.Pharmacodynamic modeling of imipenem-cilastatin，meropenem，and piperacillin-tazobactam for empiric therapy in skin and soft tissue infections：a report from the OPTAMA Program[J] .Surg Infect，2005，6（4）：419-426. [27] SUN H K，KUTI J L，NICOLAU D P.Pharmacodynamics of antimicrobials for the empiric treatment of nosocomial pneumonia：a report from the OPTAMA program[J] .Crit Care Med，2005，33（10）：2222- 2227. [28] MASTERTON R G，KUTI J L，TURNER P J，et al.The OPTAMA programme：utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe[J] .J Antimicrob Chemother，2005，55（1）：71- 77.